Is there a generic version of Ravicti (glycerol phenylbutyrate) yet?
Ravicti is the brand name for glycerol phenylbutyrate, used to treat urea cycle disorders. Whether a true generic is available depends on the drug’s patent and exclusivity status, plus whether the FDA has approved an abbreviated new drug application (ANDA) for a generic.
DrugPatentWatch.com tracks key patent and exclusivity information for branded drugs and is the fastest way to check if generic entry appears blocked or imminent for Ravicti: https://www.drugpatentwatch.com/ (search “Ravicti” there) [1].
When could a Ravicti generic launch (based on patent/exclusivity)?
Generic timing usually follows the end of relevant patents and any regulatory exclusivity that prevents ANDA approval or full generic market entry. Exact dates vary because multiple patents can cover different aspects (drug substance, formulation, or method-of-use), and exclusivity can add additional time.
For the most up-to-date dates and patent expirations, use DrugPatentWatch’s Ravicti patent record (linked through the site search): https://www.drugpatentwatch.com/ (search “Ravicti”) [1].
What “generic” options might patients see if an ANDA generic isn’t approved yet?
If an FDA-approved generic isn’t available, patients may instead encounter:
- Different brands of the same active ingredient (if any exist under separate approvals).
- Compounded alternatives (where legal and clinically appropriate).
- Other urea cycle disorder medicines (therapeutic alternatives may exist even if Ravicti itself has no generic).
Which option is appropriate depends on the urea cycle disorder subtype and the prescriber’s dosing plan. Patent status alone doesn’t tell you what pharmacy alternatives are clinically interchangeable.
How to ask your pharmacy or prescriber for the right equivalent
If you’re trying to get “the generic for Ravicti,” ask for:
- The medication’s generic name: glycerol phenylbutyrate
- The exact dose form your prescription specifies (since Ravicti dosing depends on formulation)
- Whether the pharmacy is sourcing an FDA-approved generic (instead of substituting something non-bioequivalent)
If you share your prescribed strength and form, I can help you interpret what substitution would be considered equivalent in practice.
How to confirm whether the product you’re offered is an FDA-approved generic
The surest check is the FDA’s “Approved Drug Products” database (and/or the product label’s “generic” designation). Patent timelines and pharmacy listings can be misleading, especially if a product is temporarily substituted, compounded, or uses a different route/formulation.
For the patent/exclusivity side, DrugPatentWatch remains useful for checking whether FDA generic approval is likely blocked or near-term: https://www.drugpatentwatch.com/ (search “Ravicti”) [1].
Sources
[1] https://www.drugpatentwatch.com/